How it is made
Why a forty-residue peptide costs what it does
Solid-phase synthesis is the same operation repeated once per amino acid. The arithmetic of that repetition is most of the price.
A four-residue peptide and a forty-four-residue peptide are not the same product in different sizes. They are different amounts of work, and the difference is not linear.
One residue at a time
Solid-phase synthesis anchors the first amino acid to a resin bead and grows the chain from the C-terminus up. Each cycle is the same four operations: deprotect the end of the chain, couple the next residue, cap anything that failed to couple, wash. A forty-residue peptide is forty of those cycles.
Why yield falls off a cliff
Each coupling is very efficient and not perfect. At 99 per cent per cycle — which is good — a ten-residue chain finishes at about 90 per cent. A forty-residue chain finishes at about 67. At 98 per cent per cycle, the same forty-residue chain finishes at 45.
| Residues | At 99% per cycle | At 98% per cycle |
|---|---|---|
| 10 | 90% | 82% |
| 20 | 82% | 67% |
| 30 | 74% | 55% |
| 40 | 67% | 45% |
The material that did not make it is not absent. It is in the crude as deletion sequences: chains missing one residue somewhere in the middle, chemically similar to the product and therefore genuinely hard to separate from it.
Purification is where the cost actually lands
Preparative reversed-phase HPLC pulls the product away from those near-misses. The closer the impurity is to the product, the more of the product you throw away to be rid of it. A long, difficult sequence can lose more material at the purification step than it lost during synthesis.
This is why retatrutide at thirty-nine residues with a C20 diacid on a lysine is priced where it is, and why vilon at two residues is not.
For laboratory research use only. Not a drug, not a supplement, and nothing here is a claim about what any of this material does in a person or an animal.